Cover Story
COVID-19 & CancerFree
Earlier this year, as doctors observed that patients afflicted with the novel coronavirus were dying from a cytokine release syndrome, some suggested focusing on suppressing production of interleukin-6 to control this immune response gone haywire.
Free
By Alexandria Carolan
In Brief
Funding Opportunities
Clinical Roundup
Drugs & Targets
Trending Stories
- Jeffrey S. Weber, pioneering immunologist and melanoma expert at NYU, dies at 72
- Laurie Glimcher to step down as Dana-Farber president and CEO, Benjamin Levine Ebert named successor
- Lei Zheng got his PhD in San Antonio; now he returns as cancer center director at Mays
- As NCI’s appropriations stay flat, Rathmell keeps the FY26 bypass budget steady at just under $11.5B
Rathmell: “We understand that there are real economic constraints facing our country and the world. But our gap just can’t keep widening.” - Is gastrectomy indicated?
A study recently published in JAMA suggests lower lifetime gastric cancer risk for CDH1 mutation carriers. Will this lead to changes in management recommendations? - Otis Brawley discusses health disparities, UChicago pioneering oncologists on the UChicago Cancer Luminaries Podcast